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SHORT REPORT Open Access
The lysosomal protein cathepsin L is a
progranulin protease
Chris W. Lee1,2,3*, Jeannette N. Stankowski1, Jeannie Chew1, Casey N. Cook1, Ying-Wai Lam4,5, Sandra Almeida6,
Yari Carlomagno1, Kwok-Fai Lau7, Mercedes Prudencio1, Fen-Biao Gao6, Matthew Bogyo8, Dennis W. Dickson1
and Leonard Petrucelli1*
Abstract
Haploinsufficiency of GRN, the gene encoding progranulin (PGRN), causes frontotemporal lobar degeneration
(FTLD), the second most common cause of early-onset dementia. Receptor-mediated lysosomal targeting has
been shown to regulate brain PGRN levels, and complete deficiency of PGRN is a direct cause of neuronal ceroid
lipofuscinosis (NCL), a lysosomal storage disease. Here we show that the lysosomal cysteine protease cathepsin
L (Cat L) can mediate the proteolytic cleavage of intracellular PGRN into poly-granulin and granulin fragments.
Further, PGRN and Cat L co-localize in lysosomes of HEK293 cells, iPSC-derived neurons and human cortical neurons
from human postmortem tissue. These data identify Cat L as a key intracellular lysosomal PGRN protease, and provides
an intriguing new link between lysosomal dysfunction and FTLD.
Keywords: Progranulin, Lysosome, Cathepsin L, Neutrophil elastase, Frontotemporal lobar degeneration, Neuronal
ceroid lipofuscinosis
Background
Frontotemporal dementia (FTD) is a neurodegenerative
disorder resulting from frontotemporal lobar degener-
ation (FTLD), and is characterized by progressive
changes in personality, behavior, and/or language. FTD
is the most common cause of early-onset dementia
next to Alzheimer’s disease in patients under the age
of 65 [1]. Haploinsufficiency of GRN, the gene encod-
ing progranulin (PGRN), is responsible for approxi-
mately 5–11% and 5% of clinical cases of familial and
sporadic frontotemporal dementia (i.e. FTLD-GRN),
respectively [2–5]. While complete loss of PGRN is
linked to an adult-onset form of neuronal ceroid lipo-
fuscinosis (NCL), a progressive and fatal lysosomal
storage disorder [6, 7].
PGRN is a glycoprotein with multiple downstream
effects. [8–10]. PGRN levels are regulated by sortilin
(SORT1) -mediated endocytosis and lysosomal targeting
[11, 12], and PGRN lysosomal trafficking is also regu-
lated by the prosaposin/mannose-6-phosphate receptor
(M6PR) pathway independent of SORT1 [13, 14]. In the
brain, PGRN is mainly expressed in neurons and acti-
vated microglia, and has been reported to have neuro-
trophic and neuroprotective functions, maintaining
neuronal survival and proper neurite outgrowth and
branching [9, 15–17]. PGRN contains seven and a half
tandem granulin motifs separated by linker regions and
proteolytic processing of PGRN results in the formation
of several distinct granulin proteins [8–10]. Predomin-
antly extracellular proteases, such as neutrophil elastase
[18] and MMP12 [19], have been shown to cleave the
secreted form of PGRN into mature, individual granulins
A-G, as well as intermediate poly-granulins. However,
lysosomal PGRN proteases have yet to be identified. As
specific biological roles for full-length PGRN and/or
the cleaved granulins remain unclear, it is important to
further our understanding of the mechanisms involved
in PGRN proteolytic processing.
Cathepsins are cysteine proteases acting within the
lysosomal/autophagy pathway. Interestingly, mutations
in cathepsins have been linked to NCL pathogenesis in
both humans and animal models [20, 21], while ca-
thepsin D (Cat D) levels are elevated in Grn−/− mice
and FTLD-GRN patients [22, 23]. Additionally, recent
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studies have shown that PGRN co-localizes with Cat D
in neurons [24], and that PGRN and Cat D co-
precipitate in vitro [24, 25]. We now report, for the
first time, that Cat L is a lysosomal protease that local-
izes with and proteolytically processes and degrades
intracellular PGRN in lysosomes.
Materials and methods
Cell culture
Human embryonic kidney cells 293 (HEK293) were
cultured in growth medium (DMEM supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin
streptomycin (PS) mix) in humidified incubators with
5% CO2. To knockdown PGRN, HEK293 cells were
transfected with siRNA targeting the coding region of
the GRN mRNA (Qiagen FlexiTube SI03108581) or a
non-targeting siRNA control (Qiagen Negative Control
siRNA 1,027,310). To establish Cat B, Cat L and Cat D
stable cell lines, validated human cDNA clones (Ori-
Gene) were used to amplify the corresponding cDNA.
The amplified cDNA was then subcloned into the
pCDNA4-V5His6 vector (ThermoFisher Scientific)
using the NheI and XhoI restriction sites. After trans-
fection, positive clones were selected by zeocin
(250 μg/ml) for 2 weeks. At least 50 colonies were
pooled together to generate polyclonal stable lines for
subsequence analysis. N-terminal or C-terminal 6-His
tagged PGRN expression constructs (1–593) were pre-
viously described [11]. Recombinant PGRN protein
(N-terminal 6 histidines tag) used for cell treatment
was produced by affinity purification [11].
Neurons differentiated from induced pluripotent stem
cells (iPSCs) were generated and maintained as previ-
ously described [26].
In vitro proteolytic reactions
One microgram of PGRN protein was mixed with
vehicle or the indicated amount of recombinant human
Cat L, Cat B or Cat D (R&D systems), or purified
neutrophil elastase (Athens Research & Technology),
followed by incubation at 37 °C for 15 h (Fig. 1b, c) or
for 1 h (Additional file 1: Figure S2). Cat L reactions
were carried out in a buffer containing 50 mM MES,
5 mM DTT, 1 mM EDTA adjusted to pH 4.5. Elastase
reactions were carried out in a buffer containing
100 mM Tris–HCl, 500 mM NaCl, pH 7.5. For Cat D
reaction, 20 μg/ml of Cat D was pre-activated in a buf-
fer containing 100 mM NaOAc, 150 mM NaCl, pH 4.5
buffer at 37 °C for 30 min. After pre-activation, the spe-
cified Cat D amount was applied for reaction in the
same buffer. For Cat B reaction, 10 μg/ml of Cat B was
pre-activated in a buffer containing 25 mM MES,
5 mM DTT, pH 5 buffer at 25 °C for 15 min. After pre-
activation, the specified Cat B amount was applied for
reaction in a buffer with 25 mM MES, pH 4.5. Cat L in-
hibitor I, Z-Phe-Phe-Fluoromethylketone (Z-FF-FMK),
was purchased from Santa Cruz Biotechnology.
Analysis of cysteine cathepsin activity by BMV109 probe
HEK293 cells were treated with BMV109 [27] (1/500×)
diluted in growth medium for 1 h. Labeled cells were
washed with PBS, fixed in 4% paraformaldehyde at
37 °C for 15 minutes, followed by permeabilization
with 1% triton-X in PBS for 10 minutes. To demon-
strate colocalization of active cysteine cathepsin ac-
tivity with other proteins, BMV109 probe labeled
cells were co-labeled with other antibodies as
describled in the immunocytofluorescence analysis
section below.
Liquid chromatography-mass spectrometry (LC-MS)
PGRN was proteolytically processed by recombinant Cat
L (R&D Systems) or elastase (Athen’s Research) for 16 h
by following manufacturer’s instructions. PGRN protein
in Cat L reaction buffer without protease was included
as a negative control. The reaction products were ly-
ophilized, resuspended and desalted using a 10 μl C18
tip (Pierce/ThermoFisher Scientific). Purified peptides
were then dissolved in 20 μl of a solution composed of
2.5% acetonitrile (CH3CN) and 2.5% formic acid (FA) in
water for subsequent liquid chromatography-mass
spectrometry (LC-MS) analysis. LC-MS based peptide
identification was performed on the Q-Exactive mass
spectrometer coupled to an EASY-nLC (Thermo Fisher
Scientific). Five microliters of the peptides were loaded
onto a 100 μm × 120 mm capillary column packed with
Halo C18 (2.7 μm particle size, 90 nm pore size,
Michrom Bioresources) at a flow rate of 300 nl min−1.
Peptides were separated using a gradient of 2.5–35%
CH3CN/0.1% FA for 45 min, 35–100% CH3CN/0.1% FA
for 1 min and then 100% CH3CN/0.1% FA for 8 min,
followed by an immediate return to 2.5% CH3CN/0.1%
FA and a hold at 2.5% CH3CN/0.1% FA. Peptides were
introduced into the mass spectrometer via a nanospray
ionization source and a laser pulled ~3 μm orifice with
a spray voltage of 2.0 kV. Mass spectrometry data was
acquired in a data-dependent “Top 10” acquisition
mode with lock mass function activated (m/z 371.1012;
use lock masses: best; lock mass injection: full MS), in
which a survey scan from m/z 350–1600 at 70, 000
resolution (AGC target 1e6; max IT 100 ms; profile
mode) was followed by 10 higher-energy collisional dis-
sociation (HCD) tandem mass spectrometry MS/MS
scans of the most abundant ions at 17,500 resolution
(AGC target 5e4; max IT 100 ms; centroid mode). MS/
MS scans were acquired with an isolation width of
1.6 m/z and a normalized collisional energy of 26%. Dy-
namic exclusion was enabled (peptide match: preferred;
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exclude isotopes: on; underfill ratio: 1%; exclusion dur-
ation: 30 s). Product ion spectra were searched using
the SEQUEST and Mascot search engines on Proteome
Discoverer 1.4 (Thermo Fisher Scientific) against the
human granulin sequence. Search Parameters were as
follows: no enzyme (unspecific), maximum missed
cleavages = 2, and peptides MW between 350 and 5000;
mass tolerance at 20 ppm for precursor ions and at
0.02 Da for fragment ions, and dynamic modifications
on methionines (+15.9949 Da: oxidation). The result
files were then further analyzed by Scaffold 4.3 (Prote-
ome Software) and the annotated MS/MS spectra of
the peptides identified by both SEQUEST and Mascot
were filtered by minimal XCorr cut-off values (1.3 for
singly and doubly charged peptides; 2.5 for triply
charged peptides) and mascot Ion Score value of 20
and then manually evaluated. The XCorr scores cut-offs
were set at relatively low values since most of the cleaved
peptides observed are short in length. Annotated MS/
MS spectra of the identified granulin peptides were in-
cluded in Additional file 1: Figure S2. Peptides identified
from the non-digested negative control were considered
as background and were therefore subtracted from the
peptide list generated by Cat L and elastase.
Fig. 1 Cathepsin L proteolytically processes intracellular PGRN, and in a manner distinct from elastase. a HEK293 stable cell lines stably overexpressing
pCDNA4 (pCD4), Cat B, Cat L and Cat D were analyzed for levels of PGRN and its fragments by western blot using Grn-A antibody. The expression
levels of different forms (pro-, intermediate- and mature- [40, 41]) of Cat B, Cat L and Cat D were validated in the stable cell lines. b A second,
full-length PGRN polyclonal goat antibody was applied to detect PGRN and its proteolytic fragments in HEK-Cat L cells in comparison to HEK-pCDNA4
cells (Con). c Recombinant PGRN was incubated with same amount of elastase (E), Cat B (B), Cat L (L) or Cat D (D) optimal reaction conditions. Cat L,
but not Cat B or Cat D, processed PGRN into protein fragments after the reaction. d Recombinant PGRN protein products were detected after
the addition of increasing concentrations of recombinant Cat L (left panel) or elastase (right panel). e Cleavage sites used by Cat L and elastase
on PGRN were mapped by LC/MS analysis of the small peptides produced from the in vitro proteolytic reaction. All detected peptides are listed
in Tables 1 and 2. Annotated MS/MS spectra of the identified granulin peptides were included in Additional file 1: Figure S2. Cat L and elastase
cleavage sites are labeled by blue triangle and red triangle, respectively. Common cleavage sites are highlighted by the asterisk sign. Previously
published elastase cleavage sites are labeled by green triangle. Elastase cleavage sites replicated from the current study are highlighted by plus
sign. N-glycosylation sites were highlighted in red
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Protein extraction, SDS-PAGE, and Western blotting (WB)
Cells were lysed by adding M-Per mammalian protein
extraction reagent (ThermoFisher Scientific) supple-
mented with a protease inhibitor cocktail (1% v/v) (EMD
Millipore) directly to culture plates placed on ice for
15 min with occasional mixing. Insoluble cell debris and
proteins were removed by centrifugation at 16,000 × g at
4 °C for 10 min. The M-Per soluble fraction was used
for subsequent Western blotting analysis.
Protein concentrations of cell lysates were determined
by BCA assay. Normalized protein was mixed with equal
volume of laemmli sample buffer (2×) containing 5%
(v/v) β-mercaptoethanol followed by heating for 2 min
at 85 °C. Samples were resolved using Tris-glycine 4–
20% gradient gels (ThermoFisher Scientific). For WB,
proteins were transferred onto PVDF membranes
followed by standard blocking and antibody probing
procedures. Total protein staining of gels was per-
formed using a mass spectrometry compatible silver
staining kit (ThermoFisher Scientific).
Immunocytofluorescence (ICF) analysis
Cells were grown on poly-L-lysine-coated glass cover-
slips. Cells were fixed in 4% paraformaldehyde in PBS
at 37 °C for 15 min followed by permeabilization with
1% triton-X 100 in PBS for 10 min. Cells were then
blocked in 5% non-fat milk in PBS for one hour at
room temperature, followed by incubation in primary
antibodies (in blocking solution) for 1 h at room
temperature. After washing cells in PBS twice for
10 min each, secondary antibodies conjugated to Alexa
Fluor® dye (in blocking solution) were added and incu-
bated for 1 h protected from light. After washing with
PBS, cell nuclei were stained with Hoechst 33,342 (1/
10,000× in PBS) for 15 min prior to mounting cells
onto glass slides with ProLong® Gold antifade mountant
(Invitrogen) and dried for at least 16 h at room
temperature in the dark. Images were captured using a
Zeiss LSM 880 laser scanning confocal microscope.
Immunohistofluorescence analysis (IHF)
Frontal cortical tissue sections were rehydrated in a
graded series of xylene and alcohol prior to antigen re-
trieval for 30 min in 10 mM sodium citrate, pH 6 buffer
with 0.05% tween 20. Sections were blocked in Dako
serum-free protein Block reagent (Agilent Technologies,
X0909) for 1 h at room temperature, followed by a 1 h
incubation with primary antibodies diluted in Dako
Antibody Diluent (Agilent Technologies, S2022) at room
temperature. After 3 washes with PBS, sections were
incubated with secondary antibodies conjugated with
Alexa Fluor® dye diluted in Dako Antibody Dilutent
for 1 h followed by 3 PBS washes. Sections were
mounted using Vectashield mounting medium with
DAPi and coverslipped. Mounted sections were dried
for at least 16 h at room temperature in the dark prior
to image analysis using a Zeiss LSM 880 laser scanning
confocal microscope.
Antibodies
The Grn-A antibody (Novus, 26,320,002) was used for
ICF (1:100), IHF (1:100), IHC (1:500) and WB (1:1000).
The polyclonal goat PGRN antibody (R&D systems,
AF2420) was used for WB (1:1000). Cat L antibody
(R&D Systems, AF952) was used for ICF (1:200), IHF
(1:500) and WB (1:2000). Lamp2 antibody (BD Biosci-
ences, clone H4B4) was used for ICF (1:300). Lamp1
antibody (Santa Cruz, clone E-5) was used for IHF
(1:100). NeuN (EMD Millipore, clone A60) was used
for IHF (1:100). Cathepsin D polyclonal antibody
(Athens Research & Technology, 01-12-030104) was
used for WB (1:2000). The cathepsin D antibody (Santa
cruz, clone C-20) was also used for WB (1:200). The ca-
thepsin B antibody (R&D systems, AF953) was used for
WB (1:1000). GAPDH antibody (Meridian, H86504M)
was used for WB (1: 10,000).
Lysosome purification
Lysosome purification was performed by magnetic
fractionation with minor modifications [28]. In brief,
HEK293 cells grown in 6-well culture plates were treated
with GRN transcript-specific siRNA for 72 h. The culture
medium was then replaced with medium containing
dextran-coated magnetic nanoparticles (FluidMAG-DX;
Chemicell) at a concentration of 0.5 mg/ml. After 6 h,
cells were washed three times with PBS, fresh growth
medium was added, and cells were cultured for an add-
itional hour under normal cell culture condition. Cells
were then washed twice in cold PBS and lysed in 400 μl
hypotonic buffer (10 mM HEPES pH 7.4, 10 mM NaCl,
5 mM MgCl2 and protease inhibitor cocktails (1% w/v))
for 20 min on ice. The lysed cells were then sheared with
a dounce homogenizer for 10 s in a microfuge tube,
which was then placed in a microfuge tube magnetic
separator. After 10 min, cell nuclei were removed and
the magnetic fraction containing lysosomes was retained.
The lysosomal fraction was washed twice with hypotonic
buffer. The washed magnetic fraction was then lysed in
M-Per protein extraction buffer (ThermoFisher Scien-
tific) and normalized to protein amount by BCA assay
before being analyzed by WB.
Approvals
For studies using human postmortem tissues, autopsy
consent was given by the next-of-kin and studies were
conducted with approval of the Institutional Review
Board at Mayo Clinic Florida.
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Results and discussion
Cathepsin L is a specific lysosomal PGRN protease that
cleaves PGRN into granulins
We first confirmed that PGRN is localized to the lyso-
some (Additional file 1: Figure S1a, b) and that the
PGRN antibody was specific as shown by siRNA-
mediated PGRN knockdown (Additional file 1: Figure
S1a). To determine whether cathepsin cysteine prote-
ase(s) might be responsible for intracellular PGRN pro-
teolytic processing within the lysosome, we generated
stable HEK293 lines overexpressing (OE) cathepsin B
(Cat B), Cat L or Cat D. While Cat B-OE or Cat D-OE
cells showed only minor, non-specific, reductions in
PGRN levels, Cat L-OE cells showed a shift from the
predominantly 70 kDa PGRN to lower-molecular
weight species (40 to 55 kDa) (Fig. 1a). This shift to
lower molecular weight PGRN species upon exposure
to Cat L-OE was confirmed using a second full-length
PGRN antibody (Fig. 1b). These results strongly suggest
that Cat L is a specific intracellular PGRN protease in-
volved in regulating the maturation and turnover of
PGRN within the lysosome.
To further validate the specificity of Cat L on PGRN,
we performed in vitro protease reactions on recombin-
ant PGRN with the same amount of recombinant Cat B,
Cat L or Cat D at lysosomal acidic pH under a saturated
timepoint of 15 h. Recombinant neutrophil elastase (NE)
was included as a positive control. Consistent with our
observation in a human cell system, only Cat L, but not
Cat B or Cat D, cleaved PGRN into protein products
similar in size to poly-granulin (~44 kDa to ~20 kDa)
and mono-granulin (~10 kDa) fragments. PGRN was
also processed by NE to form a 40–50 KDa fragment
under the current reaction conditions (Fig. 1c). At a
shorter time point of 1 h, Cat L also efficiently processed
PGRN into poly-granulin sized fragments at pH 4.5.
Under the same reaction condition, co-incubation with
different concentrations of Z-FF-FMK, a Cat L inhibitor,
blocked PGRN processing by Cat L in a dose-dependent
manner (Additional file 1: Figure S2). These results
further support Cat L, rather than Cat B or Cat D, as a
potential PGRN protease in the lysosome.
Previous work demonstrated that NE, a predominantly
extracellular protease, could cleave PGRN into poly-
granulins and granulins, cleaving PGRN exclusively at
linker regions to release granulins at 7 cleavage sites on
PGRN [18]. To elucidate how the lysosomal protease
Cat L cleaves PGRN, and how its cleavage activity differs
from that of NE, we performed an in vitro PGRN cleav-
age analysis using recombinant Cat L and NE under
acidic (pH 4.5) and neutral (pH 7) conditions, respect-
ively, for 15 h. Both Cat L and NE cleaved PGRN dose-
dependently, but the cleavage products generated were
distinct (Fig. 1d). Liquid chromatography-mass spec-
trometry (LC-MS)-based proteomic analyses of the Cat
L and NE small peptide products confirmed that Cat L
and NE specifically and distinctively cleaved PGRN at
multiple linker regions as well as protein regions prox-
imal to granulin/linker boundaries, with only two of the
16 Cat L cleavage sites shared with NE (Fig. 1e). Cat L
Table 1 Summary of identified peptides from Cat L proteolytic processing of PGRN
Peptide Sequence location QS SEQUEST XCorr Mascot Ion Score Δ mass (ppm)
(i) DKWPTT (Linker P – G)
CL-1 DKWPTT 47–52 2 1.46 20 −0.39
(ii) ITPTGTHPLAKKLPAQR (Linker F – B)
CL-2 ITPTGTHPLA 179–188 2 1.33 23 0.65
CL-3 KKLPAQR 189–195 2 1.78 31 −0.43
CL-4 KLPAQR 190–195 2 1.49 31 −0.29
(iii) EQGPHQVPWM (Linker A – C)
CL-5 EQGPHQVPWM(ox) 336–345 2 1.54 23 0.23
(iv) LPDPQALK (Linker A – C)
CL-6 LPDPQALK 354–361 2 1.73 36 0.20
CL-7 LPDPQAL 354–360 2 1.86 30 −0.64
CL-8 LPDPQA 354–359 1 1.57 30 −0.26
(v) AQPATF (Linker D – E)
CL-9 AQPATF 502–507 1 1.47 22 0.53
(vi) EAPRWDAPLR (Linker C-terminus end)
CL-10 EAPRWDAPLR 576–585 3 1.83 25 0.13
QS: Charge state, (ox) methionine oxidation, Δ mass (ppm), difference between experimental and theoretical masses in parts-per-million. Annotated MS/MS spectra
of the identified granulin peptides generated by Cat L activity were included in Additional file 1: Figure S2, numbered from CL-1 to CL-10
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sites were evenly distributed on linker regions between
granulin P-G, F-B, A-C, D-E and on C-terminal end,
while no Cat L sites were found on the linker G-F and
B-A (Tables 1 and 2 and Additional file 1: Figure S3)
which is likely due to interference by N-glycosylation
modifications [29]. Of note, we also detected 4 out of
the 7 NE cleavage sites identified by Ding and colleagues
[18], further validating the efficacy of our approach to
map protease cleavage sites.
Little was previously known about PGRN lysosomal
biology, partially due to a lack of understanding in how
PGRN traffics within endosomal/lysosomal compart-
ments and the functional molecular form(s) of PGRN
in the lysosome. Our data confirm that Cat L exclu-
sively cleaves PGRN on the linker regions to release
poly-granulin and mono-granulin fragments under the
acidic conditions found within lysosomes. These data
provide strong evidence to support Cat L as a novel
intracellular PGRN-to-granulin convertase, analogous
to the functional roles of NE [18] and MMP12 [19] as
extracellular PGRN proteases.
PGRN co-localizes with active Cat L in lysosomes
To confirm that Cat L acts on PGRN in human cells,
we analyzed the subcellular localization of endogenous
PGRN, Lamp2 and Cat L in HEK293 cells, induced
pluripotent stem cell (iPSC)-derived neurons [26] and
frontal cortex tissue from a sporadic FTLD patient
(negative for mutations in GRN). Immunofluorescence
(IF) results demonstrate that intracellular PGRN co-
localizes with Lamp2 and Cat-L in HEK293 and iPSC-
derived neurons (Fig. 2a–c), as well as PGRN and Cat L
co-localization in NeuN-positive neurons (Fig. 2d and e)
and partial co-localization of PGRN and Lamp2 (Fig. 2f)
in human frontal cortex. These data provide strong
indication that PGRN and Cat L co-localize within
lysosomes. Using BMV109, a quenched fluorescence
activity-based probe (qABP) that specifically labels
Table 2 Summary of identified peptides from elastase proteolytic processing of PGRN
Peptide Sequence location QS SEQUEST XCorr Mascot Ion Score Δ mass (ppm)
(i) LDKWPTLSRHLG (Linker P – G)
EL-1 LDKWPT 45–50 2 1.33 29 −0.58
EL-2 TLSRHLG 51–57 2 1.43 24 −0.62
(ii) KLPAHTV (Linker B – A)
EL-3 KLPAHTV 273–279 2 1.42 29 −0.33
(iii) PWMEKAPAHLSLPDPQAL (Linker A – C)
EL-4 PWMEKAPA 343–350 2 1.73 23 0.55
EL-5 PWM(ox)EKA 343–348 2 1.37 28 −1.70
EL-6 AHLSLPDPQ 350–358 2 1.93 23 −0.57
EL-7 HLSLPDPQAL 351–360 2 3.22 70 1.3
EL-8 HLSLPDPQA 351–359 2 1.81 36 1.2
EL-9 HLSLPDPQ 351–358 2 1.97 38 0.79
EL-10 HLSLPDP 351–357 2 1.61 40 −1.3
EL-11 HLSLP 351–355 1 1.34 23 1.0
EL-12 LSLPDPQ 352–358 1 1.75 35 0.23
(iv) VAGLEKMPA (Linker (Linker C – D)
EL-13 VAGLEKM(ox)PA 423–431 2 1.41 32 0.79
(v) TFLARSPHVGV (Linker D – E)
EL-14 TFLARSPHV 506–514 2 1.89 34 0.53
EL-15 RSPHVGV 510–516 2 1.82 33 −0.24
(vi) RWDAPLRDPAL (Linker C-terminus end)
EL-16 RWDAPLRDPAL 579–589 2 2.55 21 −0.19
EL-17 RWDAPLRDPA 579–588 3 2.94 50 2.0
EL-18 RWDAPLRDP 579–587 2 2.38 24 0.52
EL-19 RWDAPLR 579–585 2 1.98 26 −1.1
QS: Charge state, M(ox) methionine oxidation, Δ mass (ppm), difference between experimental and theoretical masses in parts-per-million. Annotated MS/MS
spectra of the identified granulin peptides generated by elastase activity were included in Additional file 1: Figure S2, numbered from EL-1 to EL-19
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active cysteine cathepsins in live cells [27], we found
triple co-localization between PGRN, BMV109 and Cat
L indicating that PGRN co-localized with active Cat L
in lysosomes (Fig. 2a and b). Collectively, these data
support the notion that PGRN is physiologically targeted
to the lysosome, where Cat L acts as an intracellular
PGRN protease within lysosomes.
Conclusions
Previous studies of PGRN in dementia largely focused
on the neurotrophic functions of full-length extracellular
PGRN. Given the predominantly lysosomal localization
of PGRN, and that it remains unclear whether full-
length and/or cleaved granulins play more important
biological roles, we focused here on exploring the me-
tabolism of intracellular PGRN within the lysosome.
One prior study using purified granulin and recombin-
ant CatL suggested that, at least in vitro, CatL had the
capacity to degrade PGRN [30]. Here, we provide evi-
dence that Cat L is, in fact, a novel mediator of intracel-
lular PGRN proteolysis, regulating levels of PGRN and
its granulin fragments. Due to an entirely unique set of
cleavage sites utilized by extracellular elastase and lyso-
somal Cat L, it is conceivable that distinct pools of poly-
granulin and granulin species are present within the
extracellular space versus in lysosomes. Further, extracel-
lular PGRN and granulins possess opposing activities in
inflammation and cell proliferation. Specifically, PGRN
suppresses inflammation and promotes cell proliferation,
whereas granulin exacerbates inflammation and inhibits
cell proliferation [18, 31]. In a recent study, granulins
were demonstrated to exacerbate TDP-43 toxicity ana-
lyzed by impaired motor function in a Caenorhabditis
elegans model [32]. While information about the regu-
lation or existence of functional and physiological gran-
ulin species within the lysosome is currently lacking,
our identification of Cat L-mediated PGRN cleavage
fragments within the lysosome open up new opportun-
ities to assess the function(s) of endogenous lysosomal
granulin species.
Though little is known about neuronal functions of
Cat L, Cat L knockout mice implicate Cat L in the pro-
duction of brain neurotransmitters including neuropep-
tide Y [33] and dynorphin [34]. Cat L also proteolytically
cleaves dynamin-1 (Dnm1), a protein that plays a key
role in the fission reaction of synaptic vesicle endocyto-
sis and synaptic transmission at nerve terminals [35] and
is involved in the pathogenesis of proteinuric kidney dis-
ease [36]. Our data identify Cat L as the first lysosomal
protease for PGRN, although future studies are needed
to assess whether cleavage of PGRN by Cat L acts as a
rate-limiting step in PGRN processing, facilitating subse-
quent cleavage events by other lysosomal proteases. In
addition, while the data presented in the current report
are suggestive of a key role for Cat L in PGRN process-
ing in neurons, additional studies performed in Cat L
knockout animals will be an intriguing new research dir-
ection to further clarify the mechanisms by which PGRN
is processed within neurons in the brain. The elucidation
of consequences on PGRN processing following altered
expression of the endogenous cathepsin L inhibitors,
cystatin C and M/E [37, 38], will also be an interesting
Fig. 2 Cellular PGRN co-localize with Cat L and active cysteine
cathepsins in lysosomes. a Immunofluorescence (IF) analysis of
HEK293 cells showing the localization of PGRN (green), Lamp2
(red) and active cysteine cathepsins (BMV109 activity probe; violet).
Nuclei in merged images were visualized by Hoechst 33,342 staining.
b IF analysis of PGRN (green), Cat L (red) and BMV109 (violet) in
HEK293 cells. c IF analysis of human wild-type iPSC-neurons showing
the localization of PGRN (green), Cat L (red), and Lamp2 (violet). d IF
analysis of neuronal cells in the frontal cortex of a sporadic FTLD
patient showing the localization of PGRN (green), Cat L (red), and
NeuN (violet). e High magnification IF analysis of Cat L (red) and
PGRN (green) in a cortical neuron from the frontal cortex. f High
magnification IF analysis of 3 representative cortical neurons in the
frontal cortex of a sporadic FTLD patient showing the localization
of PGRN (green), Lamp1 (red), and the nucleus (DAPI; blue). The
white arrows show triple co-localization (a – c) or co-localization
of PGRN and Cat L in NeuN position cells (d)
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research direction for future studies, and may represent
a novel approach to therapeutically modulate the
PGRN/granulin axis in vivo. In conclusion, as Cat L-
mediated processing of PGRN in the lysosome may be
of critical importance in the neuropathobiology of
FTLD-GRN, the current findings provide a first step
in understanding the physiological importance of Cat
L processing of PGRN in neurons.
Additional file
Additional file 1: Figure S1. (a) Isolated lysosomes and total lysate from
HEK293 cells treated with non-targeting (Con) or GRN transcript targeting
siRNA were analyzed for PGRN-specific signal by western blot using the
goat polyclonal PGRN antibody. (b) The same samples were also analyzed
for GAPDH and lysosomal markers, Lamp2 and Cat D. Figure S2. Cat L
(5 ng) efficiently processed PGRN (50 ng) into poly-granulin fragments in
1 h reaction time under pH 4.5. Under the same reaction condition, co-
incubation with Cat L inhibitor, Z-FF-FMK blocked proteolytic processing
of PGRN by Cat L in a dose-dependent manner. Figure S3. Annotated
MS/MS spectra of the identified granulin peptides shown in Fig. 1d and in
Tables 1 and 2. The Proteome Discoverer result files (.msf) were imported
into the Scaffold 4.3 (Proteome Software) for sequence annotation. The
peptides that were identified by both SEQUEST and Mascot above the
cutoff values (SEQUEST: 1.3 for singly and doubly charged peptides, 2.5
for triply charged peptides; and Mascot Ion Score: 20) were manually
evaluated PGRN peptides generated by Cat L activity were designated
as CL-1 to CL-10; whereas the PGRN peptides generated by elastase
activity were designated as EL-1 to EL-19. The fact that all the measured
precursor masses of the identified peptides were within or around
1 ppm of the theoretical masses and that the tandem mass spectra
(MS/MS) exhibit a continuous stretch of b- or y- ion series, or clear peak
assignments, indicating confident identifications. Sequence assignments
were further supported by multiple spectra of successive cleavages of
the same sequence. (DOCX 6702 kb)
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